Biocon eyes market for weight-loss drugs

Biocon Ltd plans to file for regulatory approvals of generic versions of Novo Nordisk A/S's Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on the blockbuster weight-loss drugs expire next year.

- 

The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some emerging markets, its managing director, Siddharth Mittal, told Bloomberg News.